Intetumumab in Stage IV Melanoma
Author Information
Author(s): O'Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, Schadendorf D, Thompson J A, Gonzalez R, Trefzer U, Mohr P, Ottensmeier C, Chao D, Zhong B, de Boer C J, Uhlar C, Marshall D, Gore M E, Lang Z, Hait W, Ho P
Primary Institution: The Angeles Clinic and Research Institute
Hypothesis
Does intetumumab, an anti-αv-integrin monoclonal antibody, improve outcomes in patients with stage IV melanoma when used alone or with dacarbazine?
Conclusion
Intetumumab shows a favorable safety profile and a nonsignificant trend towards improved overall survival in advanced melanoma, warranting further investigation.
Supporting Evidence
- Median overall survival was 11 months for the combination of dacarbazine and intetumumab.
- Patients receiving intetumumab alone had a median overall survival of 15 months.
- Adverse events were mostly low grade and manageable.
Takeaway
This study tested a new drug called intetumumab for patients with advanced skin cancer. It didn't show clear benefits, but it seemed safe and might help some patients live longer.
Methodology
Patients were randomly assigned to receive either dacarbazine alone, intetumumab alone, or a combination of both, and were followed for survival outcomes.
Potential Biases
Potential bias due to the open-label design and crossover treatment options.
Limitations
The study had a small sample size and high crossover rates, which may affect the results.
Participant Demographics
Patients were adults aged 18 and older with histologically confirmed stage IV melanoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website